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INTRODUCTION
Complement component 7 (C7) is one of the five terminal
complement components that generate a multi-protein com-
plex known as the membrane attack complex (MAC) upon
activation of either the classical or alternative complement
system. MAC is comprised of the complement components
C5b, C6, C7, C8, and C9. On cell membranes, this complex
becomes MAC, which is capable of forming trans-membrane
channels through which ions migrate, leading to cell lysis
and cell death (1). The killing function of MAC is best demon-
strated in individuals with a homozygous deficiency of MAC
protein: since MAC is essential to maintain localization and
to prevent dissemination of infection caused by Gram-nega-
tive organisms such as Neisseria gonorrhoeae and N. meningitides,
these individuals have increased susceptibility to develop a
disseminated disease of such infections (2).
The deficiency of C7 leads to recurrent meningococcal infec-
tions, and it is often discovered by complement assays in such
conditions (3). The C7 deficiency is an autosomal recessive
disorder and has mostly been reported in Caucasians (4). The
gene encoding the C7 protein has been assigned to the chro-
mosome band 5p13 (5). The molecular bases of C7 deficiencies
have been reported, as well as those of subtotal deficiencies
of C7 (6-8). In this report, we describe a Korean patient with
meningococcal meningitis who was diagnosed as having C7
deficiency based upon complement assays and C7 gene muta-
tion analysis. This is the first confirmed case of C7 deficien-
cy in Korea and the two mutations detected in the patient
have not been reported previously.
MATERIALS AND METHODS
Subjects
The proband, an 11-yr-old Korean girl, was admitted be-
cause of meningococcal meningitis. Laboratory screening tests
for underlying immunodeficiency revealed that the total he-
molytic activity (CH50) was undetectable in the serum of
the patient. Under the suspicion of an inherited complement
deficiency, her family members, both parents and two siblings,
were recruited for further studies after obtaining informed
consent. The total serum hemolytic activities in these family
members were within normal range (Fig. 1). Subsequent anal-
ysis by radial immunodiffusion assay with antibodies against
the main principal complement components revealed that
there was no detectable C7 in the serum of the patient, whereas
Chang-Seok Ki, Jong-Won Kim,
Hee-Jin Kim, Sung-Min Choi*, 
Gyoung-Yim Ha
� , Hee Jung Kang
� , 
Won-Duck Kim*
Department of Laboratory Medicine, Samsung Medical
Center, Sungkyunkwan University School of Medicine,
Seoul; Departments of Pediatrics* and Laboratory
Medicine
� , College of Medicine, Dongguk University,
Gyeongju; Department of Laboratory Medicine
� ,
Hallym University College of Medicine, Anyang, Korea
Address for correspondence
Won-Duck Kim, M.D.
Department of Pediatrics, Dongguk University, College
of Medicine, 707 Sukjang-dong, Gyeongju 780-714,
Korea
Tel : +82.54-770-8253, Fax : +82.54-741-2093
E-mail : neogubugi@yahoo.co.kr
*The first two authors contributed equally to this work.
220
J Korean Med Sci 2005; 20: 220-4
ISSN 1011-8934
Copyright � The Korean Academy
of Medical Sciences
Two Novel Mutations in the C7 gene in a Korean Patient with 
Complement C7 Deficiency
Complement C7 deficiency is an autosomal recessive disorder well known to be
associated with increased susceptibility to meningococcal infection and has mostly
been reported in Caucasians. In the Korean population, no case of C7 deficiency
has been reported to date. Recently we experienced an 11-yr-old girl with meningo-
coccal meningitis who was diagnosed as having C7 deficiency based upon the unde-
tectable serum C7 protein on radial immunodiffusion and the undetectable serum
total and C7 hemolytic activities. To identify the genetic basis of the C7 deficiency
of the patient, we performed a mutation analysis for the C7 gene and found two novel
mutations; a point mutation at the 3′ splice acceptor site of intron 4 (c.281-1G>T) and
a large deletion mutation encompassing almost the whole C7 gene from exon 1 to
exon 17 (c.1-?_2350+?del). A haplotype analysis showed that the large deletion
mutation was inherited from the patient’s father. To the best of our knowledge, this
is the first confirmed case of C7 deficiency in Korea.
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the C7 concentrations in the sera of both parents and younger
brother were 49-52% of the normal plasma level (reference
range, 80-120%). The functional deficiency of C7 was con-
firmed by a hemolytic assay that showed the patient’s serum
was unable to recover the hemolytic activity of C7-deficient
serum. The C6 levels of the patient and the family members
were all within normal range.
Direct sequencing of the C7 gene
Genomic DNA was isolated from peripheral blood leuko-
cytes using the Wizard Genomic DNA Purification kit ac-
cording to the manufacturer’s instructions (Promega, Madison,
WI, U.S.A.). All coding exons and flanking intron regions
of the C7 gene were amplified by using primer sets designed
by the authors (available upon request). The polymerase chain
reaction (PCR) was performed with a thermal cycler (model
9600, Applied Biosystems, Foster City, CA, U.S.A.) as fol-
lows: 32 cycles of denaturation at 94℃ for 30 sec, annealing
at 60℃ for 30 sec, and extension at 72℃ for 30 sec. The
amplicon (5 L)  was treated with 10 U shrimp alkaline phos-
phatase and 2 U exonuclease I (USB Corp., Cleveland, OH,
U.S.A.) at 37℃ for 15 min and was incubated at 80℃ for
15 min for enzyme inactivation. Cycle sequencing was per-
formed on the ABI Prism 3100 Genetic Analyzer with the
BigDye Terminator Cycle Sequencing Ready Reaction kit
(Applied Biosystems, Foster City, CA, U.S.A.).
Paternity testing and haplotype analysis
Paternity testing was performed using 5 short tandem re-
peat (STR) markers from 5 different chromosomes (D7S820,
D8S1179, D18S51, D21S11, and TH01 on chromosome
11p15.5). Haplotype analysis for the C7 gene region was per-
formed using 7 STR markers flanking the C7 gene (D5S630,
D5S416, D5S2031, D5S419, D5S1993, D5S674, and D5-
S426) and 3 intragenic single nucleotide polymorphisms
(SNP; c.665G>A, c.1166G>A, and c.1182+10G>A). All
STR markers were obtained from the ABI PRISM Linkage
Mapping Set v2.5 (Applied Biosystems) and were analyzed
on the ABI Prism 3100 Genetic Analyzer and the Genescan
software (Applied Biosystems).
Gene dosage analysis
To confirm the deletion mutation of the C7 gene, a multi-
plex PCR system was designed. The fourth exon of the low-
density lipoprotein receptor (LDLR) gene was arbitrarily se-
lected and was simultaneously amplified with each exon of
the C7 gene. After electrophoresis of the PCR products on a
2% agarose gel, the density (D) of each band was measured
by using the Gel-Doc 1000 Documentation System and Qu-
antity One Software (Bio-Rad Laboratories, Hercules, CA,
U.S.A.). Any exon with a density ratio (DR) less than 0.75, an
arbitrary cutoff, was considered as being deleted: DR={[patientDC7
exon/( patientDC7 exon+patientDLDLR exon 4)]/[controlDC7 exon/(controlDC7 exon+control
DLDLR exon 4)], where D is the band density of any exon of the
C7 gene or exon 4 of the LDLR gene.
RESULTS
The sequencing analysis indicated that the patient was a
I:1 I:2
II:1 II:2 II:3
Tests I:1 I:2 II:1 II:2 II:3 reference range
CH50 123 128 ND 124 136 77-170 CH50 unit/mL
C7 level 49 52 ND 49 89 80-120% of normal plasma
C7  916 871 ND 1,034 2,768 1,436-3,894 C7CH50 unit/mL
function
Fig. 1. Pedigree of the family with C7 deficiency. The solid circle
represents the proband (arrow) and squares/circle with a central
dot represent carriers. The table at the bottom shows the relevant
complement profile in each individual. ND, not detectable.
Fig. 2. Direct sequencing analysis of the family demonstrated a
novel G-to-T transversion (c.281-1G>T) at the 3′ splice acceptor
site of intron 4 (arrow). The patient’s mother and brother were het-
erozygous for the same mutation. However, the patient’s father did
not carry the mutation.
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homozygous carrier of a G-to-T transversion mutation in the
consensus splice-acceptor site of the intron 4 (c.281-1G>T),
presumably resulting in skipping of exon 5 of the C7 gene
during the RNA processing and splicing step. This led us
to suspect that the patient’s parents would be heterozygous
carriers of this splice-site mutation; however, the sequencing
analysis revealed that the patient’s father was homozygous for
the wild type allele for this locus, while her mother was a het-
erozygous carrier for the mutation (Fig. 2). In addition, the
patient was homozygous for three intragenic SNPs (c.665G>
A in exon 7, c.1166G>A in exon 10, and c.1182+10G>A
in intron 14), while her father was homozygous for the oppo-
site alleles for the three SNPs.
From this observation, we first performed paternity testing
with five STR markers (D7S820, D8S1179, D18S51, D21-
S11, and TH01), which indicated a paternity probability of
0.999 between the patient and his father (data not shown).
Haplotype analysis using 7 STR markers flanking the C7 gene
and 3 intragenic SNPs showed that the patient inherited bi-
parental alleles for all STR markers but had only mother’s
alleles for the c.281-1G>T mutation and all 3 intragenic SNPs
(Fig. 3). Therefore, the patient and her father were suspected
to have a large deletion mutation encompassing at least from
the splice-site mutation to intron 14 of the C7 gene. Further
analysis by a semi-quantitative gene dosage analysis using
the multiplex PCR method showed that all exons of the C7
gene except for exon 18 were deleted (Fig. 4). To delineate
the telomeric breakpoint of the deletion, three exons of the
CARD6 gene, located immediately telomeric to C7, were
tested and were shown to have a normal gene dosage, indicat-
ing that the breakpoint should lie between the CARD6 gene
and the C7 gene, whereas the centromeric breakpoint occurred
between exon 17 and exon 18 of the C7 gene (standard nomen-
clature: c.1-?_2350+?del).
The younger brother of the patient inherited the c.281-1G>
T mutation from his mother. All heterozygous carriers (the
patient’s father, mother, and younger brother) showed decreased
C7 levels and functions but had normal levels of CH50.
DISCUSSION
C7 is a single-chain polypeptide composed of 821 amino
acid residues and is structurally similar to the other compo-
nents of MAC; C6, C8 , C8 , and C9 (9, 10). The C7 gene
spans about 80 kb of DNA and is encoded by 18 exons (10).
To date, more than 15 different molecular defects leading to
total or subtotal C7 deficiency have been reported (11, 12).
Here we report two novel mutations of the gene in a Korean
family with C7 deficiency. In order to identify mutations in
the C7 gene, we performed a sequencing analysis for all exons
Fig. 3. Haplotype analysis in the family. The solid circle represents
the proband (arrow) and squares/circle with a central dot repre-
sent carriers. The patient inherited a large deletion in the C7 gene
from her father.
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Fig. 4. Gene dosage analysis by multi-
plex PCR method. (A) The fourth exon
of the LDLR gene [internal control (IC);
expected band size, 543 bp] was simul-
taneously amplified with each exon of
the C7 gene (T). The adjusted band
density of each C7 exon [Dadj=DC7 exon/
(DC7 exon+DLDLR exon 4)] in the proband was
calculated and was compared with that in a healthy control, giv-
ing a density ratio (DR) of each exon [DR=(Dadj of proband)/(Dadj
of control)], where D is the band density of any C7 exon or exon
4 of the LDLR gene.
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and their flanking introns of the gene. The patient was homo-
zygous carriers of a splicing mutation (c.281-1G>T) and three
polymorphisms of the C7 gene (c.665G>A, c.1166G>A, and
c.1182+10G>A). As expected, the patient’s mother was a
heterozygous carrier of the mutation and all three polymor-
phisms, but the patient’s father had wild type alleles for all
these variations. Extended haplotype analysis with 7 STR
markers flanking the C7 gene revealed that the patient inher-
ited a large deletion of the C7 gene from her father. Gene
dosage analysis by multiplex PCR of each exon showed that
the deletion encompassed from exon 1 to exon 17, the largest
deletion reported to date in the terminal complement defi-
ciency. The G-to-T transversion mutation in intron 4 gener-
ates a defect in the splice acceptor site and results in skipping
of exon 5 (148 bp), which is expected to produce a premature
stop codon at position 130. These mutations have led to a
loss of complement lytic function. The family study demon-
strated that the patient’s brother also carried one C7 allele
with the G-to-T transversion mutation in intron 4. Nonsense
or frameshift mutations in human disease genes frequently
cause severe reduction of corresponding mRNA and resultant
protein deficiency. Occasionally, nonsense mutations are asso-
ciated with normal mRNA levels, but truncated proteins. The
mechanisms for the reduced expression of nonsense mutated
mRNA are incompletely understood, but they seem to be
diverse and to involve cytoplasmic and nuclear rates of decay
of cytoplasmic mRNA (13, 14).
Epidemiological data on terminal complement deficiencies
show that they, as a group, are more prevalent than early com-
ponent deficiencies. In addition, there appears to be an ethnic
predilection for specific terminal complement deficiencies:
C6 and C8 - deficiencies are common in blacks, whereas
C7 and C8 deficiencies are predominantly observed in Cau-
casians. The cases of C7 deficiency have been reported more
frequently in Spanish, Israeli, and Irish than in Asians in Japan
and Korea (6, 7, 11, 12).
Of interest, there is no uniform association between any
specific geographic/ethnic group and meningococcal disease.
While there was no patient with a complement gene deficien-
cy among the survivors of Neisserial epidemics in the Faroe
Islands and Denmark (15, 16), a high prevalence of C7 defi-
ciency was noted among Moroccan Jews in Israeli populations
(17, 18). These data may reflect environmental factors such
as the endemic rate of infections and climatic differences and/
or genetic differences in the host population (19). An ancil-
lary finding in many studies of families with complement-
deficient propositus is the existence of complement-deficient
siblings who had never been infected. This also indicates dif-
ferent susceptibility among complement-deficient individu-
als with the same genetic defect, e.g., C6 deficient patients
who had survived one episode of meningococcal infection or
had never experienced an infection were shown to be at less
risk than those who had experienced recurrent infections (20).
On the other hand, the immunity to meningococcal disease
may also be determined by the interaction between IgG and
the IgG Fc receptor (Fc R) on polymorphonuclear cells (anti-
body-mediated phagocytosis). It has been hypothesized that
particular combinations of Fc R allotypes may determine
the susceptibility to meningococcal disease, especially in per-
sons who lack serum bactericidal activity because of deficiency
of a component in the terminal pathway of the complement
system (21, 22). Recent study by van der Pol et al. found that
there was no statistical significance in the association between
particular combinations of Fc R allotypes and meningococ-
cal disease (23). These authors suggested that the genetic het-
erogeneity on the long arm of chromosome 1, which is enrich-
ed with immune-modulating genes, including pentraxin,
selectin genes, and several complement regulatory proteins,
may provide important information with respect to host de-
fense against meningococci (24).
Screening for complement deficiencies is not a priority in
most countries. Routine screening of a child after meningo-
coccal disease is not necessary, if the infection is caused by
group B or C. However, an investigation is warranted if there
is a relevant past medical history such as previous suspicious
infections, an abnormal course of infective illness, infection
with non-groupable or unusual serogroups or if the current
illness is a repeated episode of neisserial infections (25). Admi-
nistration of prophylactic antibiotics should be considered in
a patient with complement deficiency, although it may encour-
age drug resistance (20). Also, vaccination with the tetravalent
polysaccharide vaccine can prevent meningococcal disease due
to the meningococcal serogroups A, C, Y, and W135 (26).
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